Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

On Apr. 29, 2011, a federal appeals court has lifted a ban on federal funding for embryonic stem cell (ESC) research. The move was celebrated by researchers hoping to use such cells for research, but it is likely that the decision will be appealed. Embryonic stem cells are pluripotent cells derived from embryonic tissue in a process that usually results in the destruction of the embryo. The ban on funding did not apply to stem cells derived from adult tissue.

The case began when a lawsuit was brought against the National Institutes of Health (NIH) by Dr. James Sherley and Dr. Theresa Deisher, scientists opposed to embryonic stem cell research.  The scientists cited a 1996 federal law called the Dickey-Wicker Amendment that prohibits funding for "research in which a human embryo or embryos are destroyed." The scientists also claimed that funding embryonic stem cell research hurt their ability to receive federal funding for their own research using adult stem cells. In August 2010, a district court agreed with the plaintiffs that embryonic stem cell research violated federal law and blocked funding, but a three-judge appeals court temporarily lifted the ban in September. The issue is whether that law's restrictions apply to research conducted on stem cell lines that had been developed without federal funding. NIH has interpreted the law narrowly, and argued that creating embryonic stem cells is not the same as using lines created without federal funding for research purposes.  In a 2-1 decision, the appeals court sided with the NIH, finding the Dickey-Wicker Amendment to be “ambiguous”, and the NIH’s interpretation reasonable.

Francis Collins III, director of the NIH, issued this statement: “I am delighted and relieved to learn of the decision of the Court of Appeals. This is a momentous day—not only for science, but for the hopes of thousands of patients and their families who are relying on NIH-funded scientists to pursue life-saving discoveries and therapies that could come from stem cell research.”

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here